Quemliclustat

Quemliclustat is an investigational agent whose form is not stated in the registry developed by Arcus Biosciences and Gilead Sciences. The sponsor describes its target as adenosine axis, which OnCo does not yet have a target page for. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT06608927 (Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma), in pancreatic ductal adenocarcinoma and non-small-cell lung cancer. The largest, NCT06608927, plans to enrol 610 participants with primary completion expected 2030-11-30. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.